Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Capital Expenditures (2016 - 2025)

United Therapeutics (UTHR) has disclosed Capital Expenditures for 17 consecutive years, with $172.9 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 99.42% to $172.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $520.5 million through Dec 2025, up 111.16% year-over-year, with the annual reading at $520.5 million for FY2025, 111.16% up from the prior year.
  • Capital Expenditures hit $172.9 million in Q4 2025 for United Therapeutics, down from $210.5 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $210.5 million in Q3 2025 to a low of -$84.8 million in Q4 2022.
  • Historically, Capital Expenditures has averaged $50.8 million across 5 years, with a median of $39.8 million in 2023.
  • Biggest five-year swings in Capital Expenditures: soared 457.38% in 2021 and later crashed 174.42% in 2023.
  • Year by year, Capital Expenditures stood at -$46.5 million in 2021, then plummeted by 82.37% to -$84.8 million in 2022, then skyrocketed by 330.66% to $195.6 million in 2023, then plummeted by 55.67% to $86.7 million in 2024, then soared by 99.42% to $172.9 million in 2025.
  • Business Quant data shows Capital Expenditures for UTHR at $172.9 million in Q4 2025, $210.5 million in Q3 2025, and $62.2 million in Q2 2025.